XML 41 R38.htm IDEA: XBRL DOCUMENT v3.20.1
Additions and Returns of Product Rights - Narrative (Details) - USD ($)
shares in Thousands
1 Months Ended 3 Months Ended 24 Months Ended
Apr. 30, 2019
Nov. 30, 2018
Nov. 30, 2016
Mar. 31, 2020
Mar. 31, 2019
Sep. 30, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Nov. 12, 2018
Agreement                    
Business Acquisition [Line Items]                    
Revenue         $ 3,200,000          
Direct expenses         2,000,000.0          
Discontinued operations income         $ 1,100,000          
Inventory               $ 500,000    
Agreement | Discontinued Operations                    
Business Acquisition [Line Items]                    
Financial consideration received in exchange for product license rights       $ 800,000            
Agreement | Scenario, Forecast                    
Business Acquisition [Line Items]                    
Financial consideration received in exchange for product license rights           $ 5,000,000        
Vibativ                    
Business Acquisition [Line Items]                    
Payment to acquire business upon closing   $ 20,000,000.0   20,000,000            
Cash payment during early 2019 $ 5,000,000.0     5,000,000            
Percentage of tiered royalty payments (up to)   20.00%                
Additional liability       7,829,848       $ 8,633,589 $ 9,502,000 $ 9,034,000
Methotrexate                    
Business Acquisition [Line Items]                    
Payment to acquire business upon closing     $ 100,000              
Liability recorded     $ 900,000              
Vested common stock, value       $ 900,000            
Methotrexate | Subsequent Event                    
Business Acquisition [Line Items]                    
Additional liability             $ 1,000,000.0      
Methotrexate | Restricted Stock                    
Business Acquisition [Line Items]                    
Unvested restricted shares (in shares)     180